CSIMarket



Best Performing Stocks In Major Pharmaceutical Preparations Industry During The Last 30 Days



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares improved by 1.84% on average, in Major Pharmaceutical Preparations Industry during the last 30 days.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




TNXP

$1.15

$0.9700 538.89%
Last 30 Days


TNXP

$1.15

$0.9700 538.89%



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp stock went up 538.89% during the last 30 days.


Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 93.011 mill. $ 10.250 mill. $ -102.616 mill. 81 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 93.011 mill.


$ 10.250 mill.


$ -102.616 mill.

Employees Shares Outstanding P/E

-


81 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SEEL

$0.9069

$0.6169 212.72%
Last 30 Days


SEEL

$0.9069

$0.6169 212.72%



Seelos Therapeutics inc

Seelos Therapeutics Inc stock improved 212.72% during the last 30 days.


Seelos Therapeutics Inc. is a biopharmaceutical company with a focus on developing innovative therapies for central nervous system disorders. They operate on a research-based business model, leveraging scientific advancements to discover and develop novel treatment options. Their goal is to address unmet medical needs in conditions such as Parkinson*s disease, Sanfilippo syndrome, and other severe neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.797 mill. $ 2.115 mill. $ -27.115 mill. 13 mill. - Y/Y -32.69 %
Market Cap. Revenues TTM Net Income TTM

$ 11.797 mill.


$ 2.115 mill.


$ -27.115 mill.

Employees Shares Outstanding P/E

-


13 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -32.69 %


MRQ Y/Y - %



INSM

$63.92

$38.9900 156.40%
Last 30 Days


INSM

$63.92

$38.9900 156.40%



Insmed Inc

Insmed Inc shares improved 156.40% during the last 30 days.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9,489.308 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 9,489.308 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



LGVN

$3.19

$1.8500 138.06%
Last 30 Days


LGVN

$3.19

$1.8500 138.06%



Longeveron Inc

Longeveron Inc stock went up 138.06% during the last 30 days.


Longeveron Inc*s business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.756 mill. $ 0.800 mill. $ -20.231 mill. 2 mill. - Y/Y -43.40 %
Market Cap. Revenues TTM Net Income TTM

$ 6.756 mill.


$ 0.800 mill.


$ -20.231 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -43.40 %


MRQ Y/Y - %



AKTX

$3.16

$1.6600 110.67%
Last 30 Days


AKTX

$3.16

$1.6600 110.67%



Akari Therapeutics Plc

Akari Therapeutics Plc shares improved 110.67% during the last 30 days.


Akari Therapeutics Plc is a biopharmaceutical company that develops and commercializes treatments for autoimmune and inflammatory diseases. Their business model revolves around conducting research, clinical trials, and obtaining regulatory approvals for their product candidates. They aim to provide innovative therapies to patients and generate revenue through the sale and licensing of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 986.467 mill. $ - mill. $ -17.748 mill. 312 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 986.467 mill.


$ - mill.


$ -17.748 mill.

Employees Shares Outstanding P/E

15


312 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SMMT

$8.39

$3.9000 86.86%
Last 30 Days


SMMT

$8.39

$3.9000 86.86%



Summit Therapeutics Inc

Summit Therapeutics Inc stock improved 86.86% during the last 30 days.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,887.978 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,887.978 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CALT

$38.77

$16.6300 75.11%
Last 30 Days


CALT

$38.77

$16.6300 75.11%



Calliditas Therapeutics Ab

Calliditas Therapeutics Ab shares increased 75.11% during the last 30 days.


Calliditas Therapeutics Ab*s business model is focused on developing and commercializing innovative pharmaceutical products to address unmet medical needs in niche markets.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,080.866 mill. $ 129.241 mill. $ -50.115 mill. 54 mill. - Y/Y 49.74 %
Market Cap. Revenues TTM Net Income TTM

$ 2,080.866 mill.


$ 129.241 mill.


$ -50.115 mill.

Employees Shares Outstanding P/E

60


54 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 49.74 %


MRQ Y/Y - %



RENB

$1.64

$0.7000 74.47%
Last 30 Days


RENB

$1.64

$0.7000 74.47%



Renovaro Inc

Renovaro Inc shares improved 74.47% during the last 30 days.


Renovaro Biosciences Inc is a biotechnology company that focuses on developing innovative therapies and technologies for regenerative medicine. Their business model involves conducting research and development, and partnering with pharmaceutical companies to bring their products to the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 176.268 mill. $ - mill. $ -53.927 mill. 107 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 176.268 mill.


$ - mill.


$ -53.927 mill.

Employees Shares Outstanding P/E

-


107 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DRRX

$1.65

$0.6900 71.88%
Last 30 Days


DRRX

$1.65

$0.6900 71.88%



Durect Corp

Durect Corp shares increased 71.88% during the last 30 days.


Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45.393 mill. $ 9.194 mill. $ -36.652 mill. 28 mill. - Y/Y -85.44 %
Market Cap. Revenues TTM Net Income TTM

$ 45.393 mill.


$ 9.194 mill.


$ -36.652 mill.

Employees Shares Outstanding P/E

-


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -85.44 %


MRQ Y/Y - %



LPCN

$9.49

$3.8700 68.86%
Last 30 Days


LPCN

$9.49

$3.8700 68.86%



Lipocine Inc

Lipocine Inc stock increased 68.86% during the last 30 days.


Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 49.679 mill. $ -2.851 mill. $ -16.352 mill. 5 mill. - Y/Y 164.58 %
Market Cap. Revenues TTM Net Income TTM

$ 49.679 mill.


$ -2.851 mill.


$ -16.352 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 164.58 %


MRQ Y/Y - %



CANF

$3.35

$1.3000 63.41%
Last 30 Days


CANF

$3.35

$1.3000 63.41%



Can fite Biopharma Ltd

Can Fite Biopharma Ltd stock improved 63.41% during the last 30 days.


Can-Fite Biopharma Ltd is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of inflammatory diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,732.750 mill. $ 0.810 mill. $ -10.173 mill. 816 mill. - Y/Y -5.04 %
Market Cap. Revenues TTM Net Income TTM

$ 2,732.750 mill.


$ 0.810 mill.


$ -10.173 mill.

Employees Shares Outstanding P/E

-


816 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -5.04 %


MRQ Y/Y - %



MNPR

$0.94

$0.3419 57.16%
Last 30 Days


MNPR

$0.94

$0.3419 57.16%



Monopar Therapeutics Inc

Monopar Therapeutics Inc shares increased 57.16% during the last 30 days.


Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 15.021 mill. $ - mill. $ -7.609 mill. 16 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 15.021 mill.


$ - mill.


$ -7.609 mill.

Employees Shares Outstanding P/E

-


16 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DERM

$5.57

$1.9800 55.15%
Last 30 Days


DERM

$5.57

$1.9800 55.15%



Journey Medical Corporation

Journey Medical Corporation shares went up 55.15% during the last 30 days.


Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 110.049 mill. $ 79.998 mill. $ -4.159 mill. 20 mill. - Y/Y 6.69 %
Market Cap. Revenues TTM Net Income TTM

$ 110.049 mill.


$ 79.998 mill.


$ -4.159 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.69 %


MRQ Y/Y - %



LSDI

$0.7751

$0.2651 51.98%
Last 30 Days


LSDI

$0.7751

$0.2651 51.98%



Lucy Scientific Discovery Inc

Lucy Scientific Discovery Inc shares went up 51.98% during the last 30 days.


Lucy Scientific Discovery Inc*s business model revolves around scientific discoveries and innovations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.678 mill. $ 0.010 mill. $ -3.684 mill. 18 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 13.678 mill.


$ 0.010 mill.


$ -3.684 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CLVR

$3.17

$1.0600 50.24%
Last 30 Days


CLVR

$3.17

$1.0600 50.24%



Clever Leaves Holdings Inc

Clever Leaves Holdings Inc shares increased 50.24% during the last 30 days.


Clever Leaves Holdings Inc operates as a vertically integrated global cannabis company. Their business model involves cultivating, processing, and distributing pharmaceutical-grade cannabis extracts and products. They aim to meet the growing demand for quality medicinal cannabis products worldwide, leveraging their expertise in research, cultivation, and distribution to serve various markets efficiently.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.968 mill. $ 16.556 mill. $ -17.899 mill. 2 mill. - Y/Y 6.42 %
Market Cap. Revenues TTM Net Income TTM

$ 4.968 mill.


$ 16.556 mill.


$ -17.899 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.42 %


MRQ Y/Y - %



RZLT

$3.95

$1.3000 49.06%
Last 30 Days


RZLT

$3.95

$1.3000 49.06%



Rezolute Inc

Rezolute Inc stock improved 49.06% during the last 30 days.


Rezolute Inc*s business model involves developing and commercializing innovative therapies, focusing on rare and severe chronic metabolic and orphan diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 200.703 mill. $ - mill. $ -58.211 mill. 51 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 200.703 mill.


$ - mill.


$ -58.211 mill.

Employees Shares Outstanding P/E

-


51 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNAZ

$1.2

$0.3934 48.77%
Last 30 Days


RNAZ

$1.2

$0.3934 48.77%



Transcode Therapeutics Inc

Transcode Therapeutics Inc stock went up 48.77% during the last 30 days.


Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.171 mill. $ - mill. $ -17.056 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.171 mill.


$ - mill.


$ -17.056 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IRON

$46.27

$14.4100 45.23%
Last 30 Days


IRON

$46.27

$14.4100 45.23%



Disc Medicine Inc

Disc Medicine Inc shares improved 45.23% during the last 30 days.


Disc Medicine Inc is a biotechnology company that focuses on developing therapeutic treatments for hematologic diseases. Their business model revolves around leveraging their expertise in hepcidin biology to discover and develop small molecules that regulate iron metabolism. By targeting and modulating specific pathways, they aim to address unmet medical needs in conditions like iron overload disorders and anemia.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,125.139 mill. $ - mill. $ -74.079 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,125.139 mill.


$ - mill.


$ -74.079 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



KTRA

$0.1833

$0.0522 39.82%
Last 30 Days


KTRA

$0.1833

$0.0522 39.82%



Kintara Therapeutics Inc

Kintara Therapeutics Inc shares improved 39.82% during the last 30 days.


Kintara Therapeutics Inc*s business model revolves around the development and commercialization of innovative therapies for the treatment of various types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.315 mill. $ - mill. $ -13.023 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.315 mill.


$ - mill.


$ -13.023 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



URGN

$19.2

$5.4200 39.33%
Last 30 Days


URGN

$19.2

$5.4200 39.33%



Urogen Pharma Ltd

Urogen Pharma Ltd shares went up 39.33% during the last 30 days.


Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 640.892 mill. $ 83.213 mill. $ -104.317 mill. 33 mill. - Y/Y 5.01 %
Market Cap. Revenues TTM Net Income TTM

$ 640.892 mill.


$ 83.213 mill.


$ -104.317 mill.

Employees Shares Outstanding P/E

-


33 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 5.01 %


MRQ Y/Y - %



MAIA

$3.95

$1.0800 37.63%
Last 30 Days


MAIA

$3.95

$1.0800 37.63%



Maia Biotechnology Inc

Maia Biotechnology Inc stock increased 37.63% during the last 30 days.


Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 54.019 mill. $ - mill. $ -5.307 mill. 14 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 54.019 mill.


$ - mill.


$ -5.307 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TERN

$8.2

$2.2100 36.89%
Last 30 Days


TERN

$8.2

$2.2100 36.89%



Terns Pharmaceuticals Inc

Terns Pharmaceuticals Inc shares improved 36.89% during the last 30 days.


Terns Pharmaceuticals Inc. is a biopharmaceutical company.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 586.547 mill. $ - mill. $ -85.013 mill. 72 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 586.547 mill.


$ - mill.


$ -85.013 mill.

Employees Shares Outstanding P/E

51


72 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IBIO

$2.56

$0.6800 36.17%
Last 30 Days


IBIO

$2.56

$0.6800 36.17%



Ibio inc

Ibio Inc shares improved 36.17% during the last 30 days.


Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.505 mill. $ - mill. $ -22.245 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 9.505 mill.


$ - mill.


$ -22.245 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNA

$39.64

$10.1300 34.33%
Last 30 Days


RNA

$39.64

$10.1300 34.33%



Avidity Biosciences Inc

Avidity Biosciences Inc stock improved 34.33% during the last 30 days.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,457.084 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,457.084 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



MREO

$4.25

$1.0800 34.07%
Last 30 Days


MREO

$4.25

$1.0800 34.07%



Mereo Biopharma Group Plc

Mereo Biopharma Group Plc stock improved 34.07% during the last 30 days.


Mereo Biopharma Group Plc*s business model focuses on the development and commercialization of innovative therapeutics for rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,422.217 mill. $ - mill. $ -34.196 mill. 570 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,422.217 mill.


$ - mill.


$ -34.196 mill.

Employees Shares Outstanding P/E

46


570 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GPCR

$48.17

$12.1000 33.55%
Last 30 Days


GPCR

$48.17

$12.1000 33.55%



Structure Therapeutics Inc

Structure Therapeutics Inc stock improved 33.55% during the last 30 days.


Structure Therapeutics Inc is a biotechnology company that utilizes a structure-based approach to develop innovative therapeutics. They focus on identifying and targeting unique protein structures to create novel drugs for various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6,729.831 mill. $ - mill. $ -97.681 mill. 140 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6,729.831 mill.


$ - mill.


$ -97.681 mill.

Employees Shares Outstanding P/E

-


140 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AFMD

$7.1

$1.7600 32.96%
Last 30 Days


AFMD

$7.1

$1.7600 32.96%



Affimed N v

Affimed N V stock increased 32.96% during the last 30 days.


Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 9.268 mill. $ -118.651 mill. - mill. - Y/Y -79.99 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 9.268 mill.


$ -118.651 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y -79.99 %


MRQ Y/Y - %



MDGL

$277.59

$65.8600 31.11%
Last 30 Days


MDGL

$277.59

$65.8600 31.11%



Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc shares increased 31.11% during the last 30 days.


Madrigal Pharmaceuticals Inc*s business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,552.236 mill. $ - mill. $ -444.275 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,552.236 mill.


$ - mill.


$ -444.275 mill.

Employees Shares Outstanding P/E

36


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CKPT

$2.12

$0.4900 30.06%
Last 30 Days


CKPT

$2.12

$0.4900 30.06%



Checkpoint Therapeutics inc

Checkpoint Therapeutics Inc shares went up 30.06% during the last 30 days.


Checkpoint Therapeutics Inc is a biopharmaceutical company that develops and commercializes immune-targeted therapies for the treatment of cancer. The company mainly focuses on acquiring, developing, and commercializing targeted immunotherapy and immuno-oncology products. Through collaborations and strategic partnerships, Checkpoint Therapeutics aims to bring innovative and effective therapies to patients while creating value for shareholders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 69.814 mill. $ - mill. $ -52.318 mill. 33 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 69.814 mill.


$ - mill.


$ -52.318 mill.

Employees Shares Outstanding P/E

19


33 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SXTP

$0.2731

$0.0631 30.05%
Last 30 Days


SXTP

$0.2731

$0.0631 30.05%



60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals Inc shares went up 30.05% during the last 30 days.


60 Degrees Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of innovative treatments for infectious diseases, particularly malaria.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.649 mill. $ 0.128 mill. $ -44.717 mill. 2 mill. - Y/Y 70.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.649 mill.


$ 0.128 mill.


$ -44.717 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 70.09 %


MRQ Y/Y - %



ESPR

$2.99

$0.6900 30.00%
Last 30 Days


ESPR

$2.99

$0.6900 30.00%



Esperion Therapeutics Inc

Esperion Therapeutics Inc stock went up 30.00% during the last 30 days.


Esperion Therapeutics Inc*s business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 567.027 mill. $ 229.740 mill. $ -86.507 mill. 190 mill. - Y/Y 466.14 %
Market Cap. Revenues TTM Net Income TTM

$ 567.027 mill.


$ 229.740 mill.


$ -86.507 mill.

Employees Shares Outstanding P/E

-


190 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 466.14 %


MRQ Y/Y - %



CMMB

$1.13

$0.2580 29.59%
Last 30 Days


CMMB

$1.13

$0.2580 29.59%



Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd stock went up 29.59% during the last 30 days.


Chemomab Therapeutics Ltd is a biotechnology company focused on developing innovative treatments for fibrosis-related diseases. Their business model revolves around the research and development of therapeutic antibodies targeting specific pathways involved in fibrosis. By leveraging their scientific expertise and strategic collaborations, the company aims to ultimately bring effective and safe therapies to market, addressing the unmet medical needs of patients suffering from fibrosis.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 265.549 mill. $ - mill. $ 24.221 mill. 235 mill. 10.97 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 265.549 mill.


$ - mill.


$ 24.221 mill.

Employees Shares Outstanding P/E

9


235 mill.


10.97

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 192.81 %



NERV

$3.33

$0.7550 29.32%
Last 30 Days


NERV

$3.33

$0.7550 29.32%



Minerva Neurosciences Inc

Minerva Neurosciences Inc shares increased 29.32% during the last 30 days.


Minerva Neurosciences Inc is a biopharmaceutical company that primarily focuses on the development and commercialization of innovative therapies for central nervous system disorders. They aim to identify potential drug candidates, conduct clinical trials, and collaborate with partners to bring novel treatments to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.205 mill. $ - mill. $ -27.709 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 25.205 mill.


$ - mill.


$ -27.709 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NGNE

$42.59

$9.0000 26.79%
Last 30 Days


NGNE

$42.59

$9.0000 26.79%



Neurogene Inc

Neurogene Inc stock increased 26.79% during the last 30 days.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 719.930 mill. $ - mill. $ -23.532 mill. 17 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 719.930 mill.


$ - mill.


$ -23.532 mill.

Employees Shares Outstanding P/E

-


17 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LSTA

$3.6

$0.7600 26.76%
Last 30 Days


LSTA

$3.6

$0.7600 26.76%



Lisata Therapeutics Inc

Lisata Therapeutics Inc shares improved 26.76% during the last 30 days.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29.858 mill. $ - mill. $ -20.876 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 29.858 mill.


$ - mill.


$ -20.876 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SLGL

$0.8801

$0.1801 25.73%
Last 30 Days


SLGL

$0.8801

$0.1801 25.73%



Sol gel Technologies Ltd

Sol Gel Technologies Ltd stock increased 25.73% during the last 30 days.


Sol Gel Technologies Ltd is a specialty pharmaceutical company that focuses on the development and manufacturing of dermatological drugs. Their business model revolves around utilizing their proprietary sol gel technology to develop innovative pharmaceutical products with enhanced drug delivery and therapeutic benefits. They primarily generate revenue by licensing or partnering with pharmaceutical companies for the commercialization of their drug products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23.839 mill. $ 1.554 mill. $ -27.238 mill. 27 mill. - Y/Y -59.98 %
Market Cap. Revenues TTM Net Income TTM

$ 23.839 mill.


$ 1.554 mill.


$ -27.238 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -59.98 %


MRQ Y/Y - %



OLMA

$12.36

$2.5100 25.48%
Last 30 Days


OLMA

$12.36

$2.5100 25.48%



Olema Pharmaceuticals inc

Olema Pharmaceuticals Inc shares improved 25.48% during the last 30 days.


Olema Pharmaceuticals Inc.*s business model focuses on the research, development, and commercialization of innovative cancer therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 555.918 mill. $ - mill. $ -96.062 mill. 45 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 555.918 mill.


$ - mill.


$ -96.062 mill.

Employees Shares Outstanding P/E

30


45 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AGIO

$44.11

$8.9300 25.38%
Last 30 Days


AGIO

$44.11

$8.9300 25.38%



Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc stock went up 25.38% during the last 30 days.


Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,487.075 mill. $ 29.403 mill. $ -352.619 mill. 56 mill. - Y/Y 46.00 %
Market Cap. Revenues TTM Net Income TTM

$ 2,487.075 mill.


$ 29.403 mill.


$ -352.619 mill.

Employees Shares Outstanding P/E

-


56 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 46.00 %


MRQ Y/Y - %



MRUS

$56.55

$11.3400 25.08%
Last 30 Days


MRUS

$56.55

$11.3400 25.08%



Merus N v

Merus N V stock went up 25.08% during the last 30 days.


Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,046.335 mill. $ 45.674 mill. $ -176.758 mill. 54 mill. - Y/Y 67.65 %
Market Cap. Revenues TTM Net Income TTM

$ 3,046.335 mill.


$ 45.674 mill.


$ -176.758 mill.

Employees Shares Outstanding P/E

-


54 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 67.65 %


MRQ Y/Y - %



DARE

$0.4498

$0.0898 24.94%
Last 30 Days


DARE

$0.4498

$0.0898 24.94%



Dar Bioscience Inc

Dar Bioscience Inc stock improved 24.94% during the last 30 days.


Dar Bioscience Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative products for women*s health. Their business model revolves around the identification of promising product candidates, conducting clinical trials to validate their safety and efficacy, and then seeking regulatory approvals and partnerships for commercialization. By addressing unmet needs in women*s health, Dar Bioscience aims to improve the quality of life for women worldwide while generating revenue through product sales and collaborations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45.211 mill. $ 2.817 mill. $ -28.874 mill. 101 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 45.211 mill.


$ 2.817 mill.


$ -28.874 mill.

Employees Shares Outstanding P/E

10


101 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com